DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

By K. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. André, V. Haddad, E. Taranchon, M. Filipits, R. Pirker, H. Popper and 6 more. New England Journal of Medicine, 2006

1,576 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/252e15d73b44b96e12ae550d75d71c4a10ac8e6d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Guido Kroemer
2. L. Galluzzi
3. Oliver Kepp
4. M. Castedo
5. Matthew D. Hall
6. Lynn M. Pouliot
7. D. Shen
8. Thomas Helleday

Citations in the corpus

• Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, neutral): “Given the current state of knowledge, the choice of adjuvant therapy should not be guided by molecular analyses such as ERCC1 or mutation testing [IV, B].”
• MicroRNA signature predicts survival and relapse in lung cancer. (2008, background): “The report that gene expression (ERCC1) can predict NSCLC patients’ response to cisplatin-based adjuvant chemotherapy was also recently reported (Olaussen et al., 2006).”
• Alternative-NHEJ Is a Mechanistically Distinct Pathway of Mammalian Chromosome Break Repair (2008, background): “Similar to the BRCA2 example, tumors deficient in ERCC1 would also be predicted to be relatively proficient at repair of DSBs by alt-NHEJ, which is consistent with the notion that DSB-inducing agents may be less effective on these tumors than interstrand crosslinking agents [44].”
• Lung cancer: Biology and treatment options. (2015, background): “Low ERCC1 expression correlates with increased sensitivity to platinum-based therapy and high ERCC1 expression correlates with better overall prognosis in NSCLC [18,19].”
• Molecular mechanisms of cisplatin resistance (2012, background): “, 1992), as well as non-small cell lung cancer (NSCLC) (Olaussen et al., 2006).”
• Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes (2012, background): “…group 1 (ERCC1) protein plays a critical role in NER and has been up-regulated in resistant ovarian cancer cell lines (Ferry et al., 2000), and a survival benefit has been found for patients with low ERCC1 (i.e., low NER capacity) in patients with metastatic lung cancer (Olaussen et al., 2006).”
• DNA repair pathways as targets for cancer therapy (2008, background): “One biological predictor of clinical outcome for patients with completely resected non-small-cell lung cancer receiving adjuvant cisplatin-based chemotherapy is expression of the excision repair cross-complementation group 1 ( ERCC1 ) protei”